TORONTO--(BUSINESS WIRE)--Medworxx Solutions Inc. ("Medworxx") (TSX VENTURE: MWX) today announced a partnership with Leidos Health (formerly part of SAIC and includes the businesses of former maxIT Healthcare and Vitalize Consulting Solutions) which formalizes their agreement to leverage each organization’s global expertise in patient flow optimization. Leidos Health employs over 2,000 healthcare consultants globally and specializes in a variety of healthcare solutions.
Medworxx and Leidos Health began working together in 2012 on a province-wide implementation of the Medworxx Patient Flow Platform for Alberta Health Services (AHS). With 8000 licensed beds, AHS was the first provincial, fully integrated health system in Canada. The success of the AHS implementation, which is contributing to significant benefits and cost savings for AHS, prompted Medworxx and Leidos to continue to pursue opportunities to assist healthcare providers in the area of patient flow performance and analytics. The two organizations collaborated to research and present; “A provincial approach to how patient flow is reducing conservable days and saving costs in the province of Alberta”. The complete case study is available at: www.medworxx.com/Leidos-AHS.
“Our experience with Medworxx has been very positive – our collective strategy is to leverage Medworxx patient flow analytics and unique data review methodology and combine this with Leidos Health’s performance improvement capability. We have introduced a program where our Clinical Performance Team will use Medworxx software and tools as a key component of our patient flow review methodology,” said Steve Comber, President of Leidos Health.
“We are excited to be working with Leidos,” said Dan Matlow, President and CEO, Medworxx. “Leidos displayed insightful clinical expertise during the AHS implementation. We are confident the depth and scope of their Clinical Performance Team has the proven ability to support our patient flow roll outs internationally. We look forward to working with Leidos consultants around the world. ”
Medworxx delivers health information solutions to over 350 hospitals internationally; including Canada, United States and United Kingdom. Medworxx helps hospitals meet patient flow challenges, and requirements in compliance and education. Medworxx Clinical Criteria – flagship of Medworxx Patient Flow that includes electronic bed board and independent assessment components – currently serves 35% of the acute care beds in Canada. Founded in 2004, Medworxx is based in Toronto, ON, and publicly traded on the TSX Venture Exchange: MWX. For more information visit: http://www.medworxx.com.
About Leidos Health
Leidos Health is a wholly owned subsidiary of Leidos [NYSE: LDOS], a national security, health and engineering solutions company. Leidos Health is committed to providing the highest quality clinical, business, and IT solutions for healthcare enterprises across the U.S. and Canada. Its services include implementation and optimizations of EHRs for all major vendors, as well as enterprise solutions focused on high-level initiatives such as Meaningful Use, ICD-10 transition, IT strategy, revenue cycle management, accountable care transformation, risk management, technology infrastructure, and project management. For more information, visit: www.LeidosHealth.com.
Leidos is a science and technology solutions leader working to address some of the world’s toughest challenges in national security, health, and engineering. The Company’s 23,000 employees support vital missions for our government and the commercial sector, develop innovative solutions to drive better outcomes, and defend our Nation’s digital and physical infrastructure from ‘new world’ threats. Leidos is headquartered in Reston, Va. and had approximately $6 billion in revenues for fiscal year 2013, on a pro forma basis, following the spin-off of the company’s technical, engineering and enterprise IT business on Sept. 27, 2013. For more information, visit: www.Leidos.com.
The statements made in this press release may contain forward-looking statements that may involve a number of risks and uncertainties. Actual events or results could differ materially from the company’s expectations and projections. The TSX Venture Exchange has not reviewed this press release and neither approved nor disapproved the information contained in this press release.